Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $8.2 million.

  • Corcept Therapeutics' Gains from Investment Securities fell 3003.18% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.4 million, marking a year-over-year increase of 4843.72%. This contributed to the annual value of $60.3 million for FY2024, which is 2660.6% up from last year.
  • Per Corcept Therapeutics' latest filing, its Gains from Investment Securities stood at $8.2 million for Q3 2025, which was down 3003.18% from $12.4 million recorded in Q2 2025.
  • Corcept Therapeutics' Gains from Investment Securities' 5-year high stood at $45.0 million during Q4 2024, with a 5-year trough of $1.2 million in Q1 2023.
  • For the 5-year period, Corcept Therapeutics' Gains from Investment Securities averaged around $10.9 million, with its median value being $5.1 million (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 150000.0% in 2021, then crashed by 8851.86% in 2022.
  • Over the past 5 years, Corcept Therapeutics' Gains from Investment Securities (Quarter) stood at $2.5 million in 2021, then surged by 652.31% to $18.9 million in 2022, then soared by 108.64% to $39.5 million in 2023, then grew by 13.83% to $45.0 million in 2024, then crashed by 81.86% to $8.2 million in 2025.
  • Its Gains from Investment Securities was $8.2 million in Q3 2025, compared to $12.4 million in Q2 2025 and $15.8 million in Q1 2025.